This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ExperGen Drug Development GmbH
Drug Names(s): CAP-232, TT-232
Description: TLN-232 is a novel seven amino-acid peptide with potential efficacy in multiple oncology indications that targets pyruvate kinase M2 (M2PK), a protein shown to be over-expressed in a number of different tumour types. M2PK is involved in tumour cell glycolysis, a process by which cancer cells generate the energy required for their rapid growth in the absence of oxygen.
Deal Structure: TLN-232 was originally discovered at the Semmelweis University in Budapest, Hungary. It was further developed by Biostatin in Budapest prior to its acquisition by ExperGen.
In March 2006, Caprion acquired the exclusive worldwide rights to the programpursuant to the TLN-232 License Agreement with ExperGen.
In March 2007, Ecopia BioSciences and Caprion Pharmaceuticals formed a new corporation - Thallion Pharmaceuticals. The common shares of Thallion will be traded on the Toronto Stock Exchange on a consolidated basis under the name Thallion and the stock symbol TLN.
In June 2010, Thallion Pharmaceuticals received notification from the Secretariat of the International Chamber of Commerce (ICC) International Court of Arbitration that the Arbitral Tribunal has rendered a partial award in favor of ExperGen (the licensor) of TLN-232.This binding award establishes that the License Agreement was duly terminated by the licensor effective December 22, 2008. The award stipulates that...See full deal structure in Biomedtracker
Additional information available to subscribers only: